<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176133</url>
  </required_header>
  <id_info>
    <org_study_id>19-004847</org_study_id>
    <nct_id>NCT04176133</nct_id>
  </id_info>
  <brief_title>Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Administration, Dose-Escalation Study of Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genome Protection, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are evaluating the safety and effectiveness of a single administration of&#xD;
      entolimod when administered at the same time as the influenza vaccine (flu vaccine).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline, day 1, day 7, 1 month, 2 months, 6 months, 12 months</time_frame>
    <description>Changes of the anti- A/H1N1, anti-A/H3N2, and anti-B influenza virus strains serum circulating antibodies (as assessed using hemagglutination inhibition (HAI) assay) levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>All onsite and phone assessments throughout the study duration, an average of 1 year</time_frame>
    <description>All adverse events (AEs)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive entolimod as a single dose administered intramuscularly (1mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive entolimod as a single dose administered intramuscularly (3mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive entolimod as a single dose administered intramuscularly (10mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a placebo as a single dose administered intramuscularly (no study drug); placebo that looks exactly like the study drug, but contains no active ingredient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entolimod</intervention_name>
    <description>Single dose administration of Entolimod</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>CBLB502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose administration, no active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Men and women of age 65 years and older at the time of enrollment&#xD;
&#xD;
          -  Eligible to receive Fluzone High-Dose&#xD;
&#xD;
          -  Female subjects must be past menopause and not pregnant&#xD;
&#xD;
          -  No history of anaphylactic reaction to gelatin, neomycin, or other vaccine component&#xD;
&#xD;
          -  Must not have had the flu vaccine within the past 90 days&#xD;
&#xD;
          -  Medically stable with no exacerbations or changes in medication regimen for chronic&#xD;
             diseases in the past 3 months and no hospitalizations in the past 6 months&#xD;
&#xD;
          -  Must be able to read/write English in order to provide informed consent and comply&#xD;
             with study procedures&#xD;
&#xD;
          -  Expected to be available for the duration of the study&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Receipt of any other vaccines within the past 30 days prior to enrollment&#xD;
&#xD;
          -  Acute illness within the last 7 days&#xD;
&#xD;
          -  History of hypersensitivity to the flu vaccine or its components (including gelatin,&#xD;
             formaldehyde, octoxinol, thimerosal, and chicken protein).&#xD;
&#xD;
          -  History of Guillain Barré syndrome (GBS)&#xD;
&#xD;
          -  History of bleeding disorders&#xD;
&#xD;
          -  Medical contraindication to treatment with vaccine as indicated by a history of&#xD;
             autoimmune disease, immune deficiency, or hypersensitivity to other vaccines.&#xD;
&#xD;
          -  Unstable major cardiovascular, renal, endocrine, immunological or hepatic disorder&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &lt; 110 mmHg or orthostatic hypotension [&gt;20 mmHg fall in&#xD;
             SBP or &gt;10 mmHg fall in diastolic blood pressure (DBP) with standing] at the time of&#xD;
             screening.&#xD;
&#xD;
          -  Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper&#xD;
             respiratory tract infections) (within 14 days prior to entolimod administration).&#xD;
             Note: Subjects with localized fungal infections of skin or nails are eligible.&#xD;
&#xD;
          -  Clinical signs of febrile illness (temperature &gt;99.5oF)&#xD;
&#xD;
          -  Baseline vital signs with ≥Grade 2 abnormalities&#xD;
&#xD;
          -  Significant cardiovascular disease (e.g., myocardial infarction, arterial&#xD;
             thromboembolism, cerebrovascular thromboembolism, venous thromboembolism) within 6&#xD;
             months prior to study drug administration; symptomatic dysrhythmias or unstable&#xD;
             dysrhythmias requiring medical therapy; angina requiring therapy; symptomatic&#xD;
             peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart&#xD;
             failure; or uncontrolled Grade ≥3 hypertension (diastolic blood pressure ≥100 mmHg or&#xD;
             systolic blood pressure ≥160 mmHg) despite antihypertensive therapy.&#xD;
&#xD;
             o Significant screening ECG abnormalities, including unstable cardiac arrhythmia&#xD;
             requiring medication, atrial fibrillation, 2nd-degree atrioventricular (AV) block type&#xD;
             II, 3rd degree AV block, or Grade ≥2 bradycardia (within 14 days prior to entolimod&#xD;
             administration).&#xD;
&#xD;
          -  Inadequate hepatic function (within 14 days prior to entolimod administration):&#xD;
&#xD;
               -  Serum alanine aminotransferase (ALT) ≥3 × upper limit of normal (ULN) (Grade ≥1).&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) ≥3 × ULN (Grade ≥1)&#xD;
&#xD;
               -  Serum alkaline phosphatase (ALP) ≥5 × ULN (Grade ≥2)&#xD;
&#xD;
          -  Serum bilirubin ≥1.5 × ULN (Grade ≥1)&#xD;
&#xD;
          -  Positive antiviral serology:&#xD;
&#xD;
               -  Positive hepatitis C virus (HCV) antibody or positive HCV ribonucleic acid (RNA)&#xD;
                  by quantitative PCR.&#xD;
&#xD;
               -  Positive hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc)&#xD;
                  antibody or undetectable hepatitis B (HBV) deoxyribonucleic acid (DNA) by&#xD;
                  quantitative polymerase chain reaction (PCR) testing.&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  Use of medication that might interact with the flu vaccine including (but not limited&#xD;
             to) specifically: aminopyrine, phenytoin sodium, theophylline, and warfarin sodium.&#xD;
&#xD;
          -  Any ongoing treatment with immunosuppressive or immune-stimulant therapy&#xD;
&#xD;
          -  Ongoing use of systemic corticosteroids.&#xD;
&#xD;
          -  Blood or blood products given within the three months prior to vaccination and two&#xD;
             months after vaccination&#xD;
&#xD;
          -  Current and/or expected receipt of chemotherapy, radiation therapy or any other&#xD;
             cytotoxic or immunosuppressive therapy [i.e. more than 10 mg of prednisone given daily&#xD;
             or on alternative days for 2 weeks or more in the past 3 months]&#xD;
&#xD;
          -  Receipt of another investigational pharmaceutical product within 60 days of treatment&#xD;
&#xD;
          -  Diagnosis of Parkinson's Disease, previous stroke, or significant cognitive impairment&#xD;
             (defined as MMSE &lt;20)&#xD;
&#xD;
          -  Other concerns that in the opinion of the PI would preclude a subject from&#xD;
             participating in study procedures or from completing the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Pignolo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Robert J. Pignolo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Geriatric</keyword>
  <keyword>Immunology</keyword>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

